Vasculitis trials
Trials closed to recruitment, in follow-up
OBIVAS
ObiVas is a randomised, phase II, double blind, controlled trial designed to evaluate the mechanistic effect of obinutuzumab versus rituximab in active AAV. Participants will be randomised to one of two treatment groups in a 1:1 ratio and receive…
